<DOC>
	<DOC>NCT01740271</DOC>
	<brief_summary>Epirubicin is a common chemotherapy medication used in the treatment of breast cancer. However, chemotherapy dosing is calculated based on people's height and weight, which may not be the most accurate way. The purpose of this study is to see if epirubicin dosing based on people's genetic profiles is better than the usual methods.</brief_summary>
	<brief_title>A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1. Female patients with histologically confirmed nonmetastatic invasive breast cancer who are scheduled to receive at least three cycles of FEC100 in the adjuvant or neoadjuvant setting 2. Documented pathological evaluation of the breast cancer for hormone receptor (estrogen receptor [ER], progesterone receptor [PR] and HER2 status 3. Eastern Cooperative Oncology (ECOG) performance status of ≤ 2 4. A Left Ventricular Ejection Fraction (LVEF) ≥ 50%. 1. Uncontrolled congestive heart failure (CHF) or angina, history of myocardial infarction within 2 months before study enrollment, or cardiac functional capacity Class III or IV as defined by the New York Heart Association Classification. 2. Psychiatric disorder(s) that would interfere with consent, study participation, or follow up.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>non-metastatic carcinoma of the breast chemotherapy</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>neoadjuvant</keyword>
</DOC>